1. Posaconazole was non-inferior to voriconazole with respect to all-cause mortality at day 42 (15% vs. 21%, respectively).
2. Incidence of treatment-related adverse events was lower for posaconazole than voriconazole.
Evidence Rating Level: 2 (Good)
Study Rundown: Invasive aspergillosis (IA) is a life-threatening infection that commonly occurs in patients with immunosuppression. Currently,...